Blincyto Kit
Product Images NDC 55513-160

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Blincyto (NDC 55513-160). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Kaplan Meier Curve Of Overall Survival In Tower Study (Blincyto 01)

A Kaplan-Meier survival curve graph comparing overall survival probability over 27 months for Blincyto (blinatumomab) and standard-of-care chemotherapy (SOC Chemo) groups. The graph includes median overall survival (OS) times, hazard ratio (HR) with confidence intervals, p-value, and the number of subjects at risk over time, with censoring indicated by vertical bars.*

FDA Label Image

Blincyto 02

Label of BLINCYTO (blinatumomab) for Injection, 35 mcg per vial, manufactured by Amgen, Inc. It is a single-dose vial intended for intravenous infusion only. The label includes storage instructions (2°C to 8°C) and a note that the vial contains no preservative. The label emphasizes not to shake the reconstituted solution and mentions dispensing the enclosed medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.